Publikationen (Auswahl) Stand 03/2022 (Link)

Mevius A, Brandes A, Hardtstock F, Wilke T, Ratsch BA, Orzechowski HD, Fuchs A, Deiters B, Bokemeyer B. Persistence with Biologic Treatment in Patients with Inflammatory Bowel Disease: A German Claims Data Analysis (2021). Digestion. 2021;102:216-226. doi: 10.1159/000503859. Epub 2019 Oct 22. PMID: 31639807.Link

Langbrandtner J, Steimann G, Reichel C, Bokemeyer B, Hüppe A. Work-Related Problems and Requested Support in Inflammatory Bowel Disease - Results of a Multi-Perspective Survey (2021). Rehabilitation (Stuttg). 2021;60:29-36. doi: 10.1055/a-1248-5703. Epub 2020 Nov 5. PMID: 33152779 German.Link

Ghiani M, Naessens D, Takacs P, Myers D, Bokemeyer B, Wilke T. Long-term cost and complications of surgery in patients with ulcerative colitis: a claims data analysis (2021). Int J Colorectal Dis. 2021;36:831-840. doi: 10.1007/s00384-021-03876-z. Epub 2021 Feb 10. PMID: 33569628.Link

Di Giuseppe R, Plachta-Danielzik S, Mohl W, Hoffstadt M, Krause T, Bokemeyer B, Schreiber S. Profile of patients with inflammatory bowel disease in conjunction with unmet needs and decision-making for choosing a new biologic therapy: a baseline analysis of the VEDOIBD-Study (2021). Int J Colorectal Dis. 2021:8. doi: 10.1007/s00384-021-03943-5. Online ahead of print. PMID: 33963913.Link

Howaldt S, Domènech E, Martinez N, Schmidt C, Bokemeyer B. Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial (2021). Inflamm Bowel Dis. 2021;14:izab073. doi: 10.1093/ibd/izab073. Online ahead of print. PMID: 33988236.Link

Bokemeyer B, Ghiani M, Fuchs A, Deiters B, Hardtstock F, Brandes A, Knop J, Orzechowski HD, Wilke T. Indicators of active disease and steroid dependency in patients with inflammatory bowel diseases not treated with biologics in a German real-world-setting. Int J Colorectal Dis. 2020;35(8):1587-1598. doi: 10.1007/s00384-020-03588-w. Epub 2020 May 18. PMID: 3242452.Link

Adamina M, Bonovas S, Raine T, Spinelli A, Warusavitarne J, Armuzzi A, Bachmann O, Bager P, Biancone L, Bokemeyer B, Bossuyt P, Burisch J, Collins P, Doherty G, El-Hussuna A, Ellul P, Fiorino G, Frei-Lanter C, Furfaro F, Gingert C, Gionchetti P, Gisbert JP, Gomollon F, González Lorenzo M, Gordon H, Hlavaty T, Juillerat P, Katsanos K, Kopylov U, Krustins E, Kucharzik T, Lytras T, Maaser C, Magro F, Marshall JK, Myrelid P, Pellino G, Rosa I, Sabino J, Savarino E, Stassen L, Torres J, Uzzan M, Vavricka S, Verstockt B, Zmora O. ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. J Crohns Colitis. 2020 Feb 10;14:155-168. Link

Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, Adamina M, Armuzzi A, Bachmann O, Bager P, Biancone L, Bokemeyer B, Bossuyt P, Burisch J, Collins P, El-Hussuna A, Ellul P, Frei-Lanter C, Furfaro F, Gingert C, Gionchetti P, Gomollon F, González-Lorenzo M, Gordon H, Hlavaty T, Juillerat P, Katsanos K, Kopylov U, Krustins E, Lytras T, Maaser C, Magro F, Marshall JK, Myrelid P, Pellino G, Rosa I, Sabino J, Savarino E, Spinelli A, Stassen L, Uzzan M, Vavricka S, Verstockt B, Warusavitarne J, Zmora O, Fiorino G. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment (2020). J Crohns Colitis. 2020;14(1):4-22. doi: 10.1093/ecco-jcc/jjz180. PMID: 31711158.Link

Petersen BS, Bokemeyer B, Wenker C, Hoby S, Baumgartner K, Höppner MP, Schreiber S, Mecklenburg I, Franke A; *these authors contributed equally. First known case of pediatric inflammatory bowel disease in a western lowland gorilla may be linked to a familial mutation in the MEFV gene. Gut. 2019 Jun; 69(6):1153-1154. pii: gutjnl-2019-319051. doi: 10.1136/gutjnl-2019-319051.Link

Mevius A, Brandes A, Hardtstock F, Wilke T, Ratsch BA, Orzechowski HD, Fuchs A, Deiters B, Bokemeyer B. Persistence with Biologic Treatment in Patients with Inflammatory Bowel Disease: A German Claims Data Analysis. Digestion. 2019; 22:1-11. doi:  10.1159/000503859. Link

Stallmach A, Bokemeyer B, Helwig U, Lügering A, Teich N, Fischer I, Rath S, Lang D, Schmidt C; EPIC Study Group. Predictive parameters for the clinical course of Crohn's disease: development of a simple and reliable risk model. Int J Colorectal Dis. 2019;34:1653-1660. Link

Brandes A, Groth A, Gottschalk F, Wilke T, Ratsch BA, Orzechowski HD, Fuchs A, Deiters B, Bokemeyer B. Real-world biologic treatment and associated cost in patients with inflammatory bowel disease. Z Gastroenterol. 2019;57:843-851. doi: 10.1055/a-0903-2938.  Link

Rivas MA, Avila BE, Koskela J, Huang H, Stevens C, Pirinen M, Haritunians T, Neale BM, Kurki M, Ganna A, Graham D, Glaser B, Peter I, Atzmon G, Barzilai N, Levine AP, Schiff E, Pontikos N, Weisburd B, Lek M, Karczewski KJ, Bloom J, Minikel EV, Petersen BS, Beaugerie L, Seksik P, Cosnes J, Schreiber S, Bokemeyer B, Bethge J; International IBD Genetics Consortium; NIDDK IBD Genetics Consortium; T2D-GENES Consortium, Heap G, Ahmad T, Plagnol V, Segal AW, Targan S, Turner D, Saavalainen P, Farkkila M, Kontula K, Palotie A, Brant SR, Duerr RH, Silverberg MS, Rioux JD, Weersma RK, Franke A, Jostins L, Anderson CA, Barrett JC, MacArthur DG, Jalas C, Sokol H, Xavier RJ, Pulver A, Cho JH, McGovern DPB, Daly MJ. Correction: Insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population. PLoS Genet. 2019;30;15:e1008190. doi: 10.1371/journal.pgen.1008190. eCollection 2019 May. Link

Bokemeyer B, Luehr D, Helwig U, Maaser C, Jessen P, Schreiber S. Small bowel capsule endoscopy in ulcerative colitis: the capcolitis study: a prospective observational study. Eur J Gastroenterol Hepatol. 2019;31:766-772. doi: 10.1097/MEG.0000000000001410. Link

Petruo VA, Krauss E, Kleist A, Hardt J, Hake K, Peirano J, Krause T, Ehehalt R, von Arnauld de la Perriére P, Büning J, Treml O, Krauss N, Albrecht H, Felten G, Hermannspahn U, Burkhardt U, Eisold M, Teich N, Siegmund B, Maaser C, Bokemeyer B, Baumgart DC, Neurath MF, Mudter J; German IBD Study Group (GISG) KND. Perceived distress, personality characteristics, coping strategies and psychosocial impairments in a national German multicenter cohort of patients with Crohn's disease and ulcerative colitis. Z Gastroenterol. 2019;57:473-483. doi: 10.1055/a-0838-6371. Link

Feagan BG, Schreiber S, Wolf DC, Axler JL, Kaviya A, James A, Curtis RI, Geransar P, Stallmach A, Ehehalt R, Bokemeyer B, Khalid JM, O'Byrne S. Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis. Inflamm Bowel Dis. 2019.;4;25:1028-1035. doi: 10.1093/ibd/izy323. Link

Rivas MA, Avila BE, Koskela J, Huang H, Stevens C, Pirinen M, Haritunians T, Neale BM, Kurki M, Ganna A, Graham D, Glaser B, Peter I, Atzmon G, Barzilai N, Levine AP, Schiff E, Pontikos N, Weisburd B, Lek M, Karczewski KJ, Bloom J, Minikel EV, Petersen BS, Beaugerie L, Seksik P, Cosnes J, Schreiber S, Bokemeyer B, Bethge J; International IBD Genetics Consortium; NIDDK IBD Genetics Consortium; T2D-GENES Consortium, Heap G, Ahmad T, Plagnol V, Segal AW, Targan S, Turner D, Saavalainen P, Farkkila M, Kontula K, Palotie A, Brant SR, Duerr RH, Silverberg MS, Rioux JD, Weersma RK, Franke A, Jostins L, Anderson CA, Barrett JC, MacArthur DG, Jalas C, Sokol H, Xavier RJ, Pulver A, Cho JH, McGovern DPB, Daly MJ. Insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population. PLoS Genet. 2018 May 24;14(5):e1007329. doi: 10.1371/journal.pgen.1007329. eCollection 2018 May. Erratum in: PLoS Genet. 2019;30;15:e1008190. Link

Hüppe A, Langbrandtner J, Häuser W, Raspe H, Bokemeyer B. Validation of the "German Inflammatory Bowel Disease Activity Index (GIBDI)": An Instrument for Patient-Based Disease Activity Assessment in Crohn's Disease and Ulcerative Colitis. Z Gastroenterol. 2018t;56:1267-1275. doi: 10.1055/a-0605-4080. Link

Wittig BM, Sabat R, Holzlöhner P, Witte-Händel E, Heilmann K, Witte K, Triebus J, Tzankov A, Laman JD, Bokemeyer B, Terracciano L, Schwärzler C, Kohler H, Volkmer R, Loddenkemper C, Wolk K, Hoffmann U, Günthert U. Absence of specific alternatively spliced exon of CD44 in macrophages prevents colitis. Mucosal Immunol. 2018;11:846-860. Link

Langbrandtner J, Huppe A, Jessen P, Buning J, Nikolaus S, Raspe H, Bokemeyer B. Quality of care in inflammatory bowel disease: results of a prospective controlled cohort study in Germany (NETIBD). Clin Exp Gastroenterol 2017; 10: 215-27. Link

Hartmann P, Bokemeyer B. Anti-TNF-α--Wirkstoffe bei chronisch entzündlichen Darmerkrankungen (2017). Pharmakon 2017;5:356-364. Link

Lindsay JO, Armuzzi A, Gisbert JP, Bokemeyer B, Peyrin-Biroulet L, Nguyen GC, Smyth M, Patel H. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease(2017). Dig Liver Dis. 2017 Aug 1. pii: S1590-8658(17)30985-4. doi: 10.1016/j.dld.2017.07.010. Link

Teich N, Mohl W, Bokemeyer B, Bündgens B, Büning J, Miehlke S, Hüppe D, Maaser C, Siegmund B, Schmidt C, Stallmach A, German IBD Study group. Azathioprine allows glucocorticoid withdrawal - post hoc results of a prospective study in patients with inflammatory bowel diseases (2017). Z Gastroenterol. 2017;55:461-465. doi: 10.1055/s-0043-106310. Link

Bokemeyer B, Dignaß A, Schreiber S. Biosimilars in Inflammatory Bowel Disease (IBD): Experiences and perceptions of german gastroenterologists (2017). Z Gastroenterol. 2017;55(4):369-374. Link

Teich N, Bokemeyer B, Mohl W, Walldorf J, Bruns T, Schmidt C, Stallmach A; German IBD Study Group. Blood group B is associated with azathioprine-induced acute pancreatitis in patients with IBD (2017). Gut. 2017;66(8):1531-1532. Link

Schmidt C, Ahmad T, Tulassay Z, Baumgart DC, Bokemeyer B, Howaldt S, Stallmach A, Büning C; AEGIS Study Group. Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a Phase 3 study (2017). Aliment Pharmacol Ther. 2016 Aug;44(3):259-70. Link

Bokemeyer B, Krummenerl A, Maaser C, Howaldt S, Mroß M, Mallard N. Randomized Open-Label Phase 1 Study of the Pharmacokinetics of Ferric Maltol in Inflammatory Bowel Disease Patients with Iron Deficiency (2017). Eur J Drug Metab Pharmacokinet. 2017;42(2):229-238. Link

Stallmach A, Bokemeyer B, Axler J, Curtis R, Ehehalt R, Feagan B, Geransar P, James A, Kaviya A, Khalid J.M, Wolf D, Schreiber S. DOP026 Sustained remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis of week 14 remitters (2017). Journal of Crohn s and Colitis 11;S42-S43. Link

Kruis W, Leifeld L, Hoepffner N, Hoesl M, Jessen P, Mross M, Klugmann T, Ceplis-Kastner S, Reimers B, Bokemeyer B. A Prospective Study to Predict a Mild Course of Crohn's Disease: An Interim Analysis of the Prognos-Study (2017). Gastroenterol. 2017;152;377. Link

Siegel, CA, Lichtenstein G, Siegmund B, Lewis JD, Wolf D, Luous E, Sebastian S, Hebuterne X, Bell A, Södermann C, Schuber S, Atreya R, Polyak S, Hoque S, Krummenerl A, Bokemeyer B, Krummenerl T, Shulmann S, Karlén P, Moum B, Dolin P. P501 Baseline characteristics of Crohn's disease patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (02) 2017. J Crohns Colitis; 11: S333-S334. Link

Bokemeyer B, Schreiber S. Versorgungsfokus. CED chronisch-entzündliche Darmerkrankungen. Arbeitsgemeinschaft Pro Biosimilars. 2016. probiosimilars.de/publikationen/versorgungsfokus-ced. Link

Schreiber S, Hartmann H, Kruis W, Kucharzik T, Mudter J, Siegmund B, Stallmach A, Witte C, Fitzke K, Bokemeyer B. Inflammatory Bowel Disease Competence Network (2016). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 201;59(4):465-74. Link

Teich N, Mohl W, Bokemeyer B, Bündgens B, Büning J, Miehlke S, Hüppe D, Maaser C, Klugmann T, Kruis W, Siegmund B, Helwig U, Weismüller J, Drabik A, Stallmach A; German IBD Study Group. Azathioprine-induced Acute Pancreatitis in Patients with Inflammatory Bowel Diseases--A Prospective Study on Incidence and Severity (2016). J Crohns Colitis. 2016 Jan;10(1):61-8. Link

Siegmund B, Atreya R, Bokemeyer B, Kruis W, Mudter J, Sander C, Schreiber S, Reindl W, Zeissig S, Kucharzik T. Biosimilars in inflammatory bowel disease (2016). Z Gastroenterol. 2016;54;1217-1222. Link

Sternkopf J, Bokemeyer B, Tappe U, Schultz C. Potenziale einer integrierten Versorgung (2016). Deutsches Ärzteblatt 113;46;A2090-2092 Link

Peyrin-Biroulet L, Armuzzi A, Gisbert JP, Nguyen GC, Bokemeyer B, Lindsay J, Smyth M, Munsaka M, Ramagopalan S, Khalid JM. OP008. Predictors of NON-Response or loss of response to tumour necrosis factor antagonist therapies in inflammatory bowel disease (2016). United European Gastroenterology Journal 4 Supplement 1;4. Link

Kontakt: bernd.bokemeyer@t-online.de